Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
9.32
+0.24 (2.60%)
Nov 21, 2024, 1:28 PM EST - Market open
Enanta Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ENTA stock have an average target of 19.67, with a low estimate of 10 and a high estimate of 27. The average target predicts an increase of 111.13% from the current stock price of 9.32.
Analyst Consensus: Buy
* Price targets were last updated on Oct 10, 2024.
Analyst Ratings
The average analyst rating for ENTA stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 2 | 1 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +189.81% | Oct 10, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $22 | Buy | Reiterates | $22 | +136.14% | Oct 9, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $22 | Buy | Reiterates | $22 | +136.14% | Sep 27, 2024 |
| JP Morgan | JP Morgan | Sell Maintains $11 → $10 | Sell | Maintains | $11 → $10 | +7.34% | Aug 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +189.81% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
72.64M
from 79.20M
Decreased by -8.29%
Revenue Next Year
76.37M
from 72.64M
Increased by 5.14%
EPS This Year
-5.38
from -6.38
EPS Next Year
-4.92
from -5.38
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 77.3M | 117.5M | 114.7M | |||
| Avg | 72.6M | 76.4M | 77.0M | |||
| Low | 67.7M | 63.0M | 34.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.4% | 61.8% | 50.2% | |||
| Avg | -8.3% | 5.1% | 0.8% | |||
| Low | -14.5% | -13.3% | -55.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -5.07 | -4.28 | -3.20 | ||
| Avg | -5.38 | -4.92 | -5.79 | ||
| Low | -5.51 | -5.75 | -8.50 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.